New research in mice suggests a way to reverse Alzheimer’s-related brain changes by restoring a key cellular energy molecule, offering a clear laboratory signal that rebalancing brain energy may stop — and even undo — disease markers that were long thought permanent.
Scientists at University Hospitals Cleveland Medical Center studied two mouse models of Alzheimer’s and compared findings with human brain tissue, spotting a sharp drop in levels of the cellular cofactor NAD+. NAD+ is central to cellular energy production and maintenance, and the team focused on whether restoring it could change the course of disease in animals.
NAD+ naturally declines with age, and the senior author explained the consequence plainly: “When NAD+ falls below necessary levels, cells cannot effectively perform essential maintenance and survival functions.” That loss of cellular upkeep can leave neurons vulnerable to the amyloid and tau pathology linked to dementia.
Outside experts noted the brain’s voracious energy needs. “The brain consumes around 20% of your body’s energy and has high demand for NAD+ for cellular energy production and DNA repair,” one scientist said, highlighting why a metabolic approach to neurodegeneration is biologically plausible.
The team used a small molecule called P7C3-A20 to restore NAD+ balance in mice, and the results were striking in the lab. In animals treated before heavy pathology set in, the drug blocked the onset of Alzheimer’s-like changes; in mice with advanced disease, it reversed amyloid and tau accumulation and restored cognitive performance in behavioral tests.
Treated animals also showed normalized blood levels of phosphorylated tau 217, an emerging clinical biomarker that clinicians track in human Alzheimer’s research. That biochemical normalization makes the finding more than a curiosity in a dish; it suggests a measurable impact on pathways scientists already use to follow human disease.
Lead researchers found the degree of reversal surprising and said it challenges long-standing assumptions. “For more than a century, Alzheimer’s has been considered irreversible,” one investigator said. “Our experiments provide a proof of principle that some forms of dementia may not be inevitably permanent.”
The authors were “struck” by how robustly advanced disease was reversed when NAD+ homeostasis was restored, even though the treatment did not target amyloid plaques directly. “This gives reason for cautious optimism that similar strategies may one day benefit people,” the study team added, while urging measured expectations.
Important caveats remain: the entire study was done in mouse models, and the researchers emphasized that animal success does not guarantee human benefit. “Alzheimer’s is a complex, multifactorial, uniquely human disease,” they warned, noting that translating a metabolic fix from rodents to people is a major scientific step that requires clinical testing.
The group also flagged safety concerns around over-the-counter NAD+-boosting supplements, noting data in some animal systems that excessive NAD+ could promote cancer. “P7C3-A20, by contrast, enables cells to restore and preserve appropriate NAD+ balance under stress without driving NAD+ to excessively high levels,” the investigators wrote.
Alongside pharmacology, the researchers reiterated lifestyle measures that support brain resilience. “These include prioritizing sufficient sleep, following a MIND or Mediterranean diet, staying cognitively and physically active, maintaining social connections, addressing hearing loss, protecting your head from physical injury, limiting alcohol, and controlling blood pressure and other cardiovascular risk factors like avoiding smoking,” Pieper advised.
Next steps will probe whether restoring brain energy balance helps other age-related neurodegenerative conditions and whether the P7C3-A20 approach can be advanced safely into human trials. For now, the work offers a biological foothold: restoring metabolic balance in the brain can reverse key disease markers in animals, and that finding will guide the next wave of research into therapies for dementia.
